Lisata Therapeutics, INC. (LSTA) — SEC Filings

Latest SEC filings for Lisata Therapeutics, INC.. Recent 10-Q filing on Nov 6, 2025. AI-decoded analysis of earnings, risk factors, and insider trades.

View Lisata Therapeutics, INC. on SEC EDGAR

Overview

Lisata Therapeutics, INC. (LSTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Lisata Therapeutics, Inc. (LSTA) reported a net loss of $4.249 million for the three months ended September 30, 2025, an improvement from the $4.930 million net loss in the same period of 2024. For the nine months ended September 30, 2025, the net loss was $13.632 million, down from $15.375 million

Sentiment Summary

Across 21 filings, the sentiment breakdown is: 20 neutral, 1 mixed. The dominant filing sentiment for Lisata Therapeutics, INC. is neutral.

Filing Type Overview

Lisata Therapeutics, INC. (LSTA) has filed 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K with the SEC between Feb 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (21)

Lisata Narrows Q3 Loss, Delays Phase 3 Amid Cash Management — 10-Q · Nov 6, 2025 Risk: high
Lisata Therapeutics, Inc. (LSTA) reported a net loss of $4.249 million for the three months ended September 30, 2025, an improvement from the $4.930 million net
Lisata Therapeutics Files 8-K — 8-K · Oct 14, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Lisata Therapeutics Enters Material Definitive Agreement — 8-K · Oct 8, 2025 Risk: medium
On October 8, 2025, Lisata Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Caladrius Biosciences, Inc., is incor
10-Q Filing — 10-Q · Aug 7, 2025
Lisata Therapeutics Files 8-K — 8-K · Jul 15, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on July 15, 2025, reporting on other events and financial statements. The company, formerly known as Caladrius Bioscience
Lisata Therapeutics Files 8-K — 8-K · Jun 26, 2025 Risk: low
On June 26, 2025, Lisata Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. L
8-K Filing — 8-K · Jun 17, 2025
8-K Filing — 8-K · Jun 13, 2025
Lisata Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Jun 10, 2025 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on June 10, 2025, to report on the submission of matters to a vote of security holders. The company, formerly known as Ca
Lisata Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc., is
Lisata Therapeutics Executive Compensation Revealed — DEF 14A · Apr 25, 2025 Risk: medium
Lisata Therapeutics, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing include
10-K Filing — 10-K · Feb 27, 2025
LISATA THERAPEUTICS, INC. Files 8-K — 8-K · Jan 23, 2025 Risk: low
On January 22, 2025, LISATA THERAPEUTICS, INC. filed an 8-K report. The filing indicates that the company's common stock is registered and traded on The Nasdaq
Lisata Therapeutics Enters Material Definitive Agreement — 8-K · Dec 3, 2024 Risk: medium
On December 3, 2024, Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.) entered into a Material Definitive Agreement. The company, incorporated in
Lisata Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business o
Lisata Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 12, 2024 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op
Lisata Therapeutics Files 8-K on Financials — 8-K · Jun 27, 2024 Risk: low
Lisata Therapeutics, Inc. filed an 8-K on June 27, 2024, to report on its results of operations and financial condition. The company, formerly known as Caladriu
Lisata Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: low
LISATA THERAPEUTICS, INC. (LSTA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lisata Therapeutics, Inc. filed a 10-Q report on May 9, 2024, for
Lisata Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
LISATA THERAPEUTICS, INC. (LSTA) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Lisata Therapeuti
Lisata Therapeutics Appoints New Director — 8-K · Apr 17, 2024 Risk: low
Lisata Therapeutics, Inc. announced on April 15, 2024, a change in its Board of Directors. Specifically, Dr. Philip P. Vanek has been appointed as a new directo
Lisata Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
LISATA THERAPEUTICS, INC. (LSTA) filed a Annual Report (10-K) with the SEC on February 29, 2024. Lisata Therapeutics, Inc. (formerly Caladrius Biosciences, Inc.

Related Companies

CLBS · LISATA

Frequently Asked Questions

What are the latest SEC filings for Lisata Therapeutics, INC. (LSTA)?

Lisata Therapeutics, INC. has 21 recent SEC filings from Feb 2024 to Nov 2025, including 11 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of LSTA filings?

Across 21 filings, the sentiment breakdown is: 20 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Lisata Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Lisata Therapeutics, INC. (LSTA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.